We aim to be the company with the highest impact on patient's lives and highest doctor satisfaction.

What is Mrimath’s vision?

It’s not hard to make decisions once you know what your values are.

What is AI in the brain cancer care?

Speed up segmentation, volumetric, and accurate radiation therapy planning with MRIMath AI.

Artificial intelligence (Al) makes it possible for machines to learn from experience, adjust to new inputs and perform human-like tasks.

Malignant brain tumors typically arise when glial cells such as astrocytes and oligodendrocytes, acquire new capabilities including uncontrolled cell replication, the ability to migrate or invade the surrounding brain tissue, and the ability to create new blood channels that support high density cells with oxygen and nutrients. Generally, brain tumors are graded from 1 to 4, according to their behavior, such as how fast they grow and how fast they migrate and how likely they are to grow back after treatment. A malignant brain tumor is either grade 3 or 4, whereas grade 1 or 2 tumors are associated with a better prognosis than higher grades. Most malignant tumors are secondary cancers, which means they started in another part of the body and metastasize to the brain. Primary brain tumors originate in the brain.

MRIMath is at the forefront of trustworthy and responsible artificial intelligence in wide scale application .

What is AI in the brain cancer care?

Phase 1: Combined chemo and radiation therapy
a. radiation therapy, Monday-through Friday, for 5-6 weeks.
b. Temodar chemotherapy, daily from first to last day of radiation, including weekends.
c. anti-nausea medicine.
Phase 2.
Higher dose of Temodar for 5 consecutive days/28-day cycle, repeated for 6 cycles.
MRI imaging at diagnosis, postop, one month after radiation, every two cycles during chemo, then every 3 months for 2 years. After that, they are spaced out.

Primary VS Secondary GBM Glioblastoma multiforme (GBM) is a malignant brain tumor. There are two types of GBM:
• Primary (de novo) is the most common and the most aggressive form.
• Secondary usually starts from a lower-grade glioma and is associated with mutations in the isocitrate dehydrogenase gene (IDH) and better prognosis.

-Methyl Guanine Methyl Transferase (MGMT) Methylation status predicts the response of malignant glioma to chemotherapy and patients’ survival.
-MGMT is a protein in cells, including tumor cells, that repairs damage to the cell’s DNA caused by Temozolomide (Temodar) chemotherapy.
-The more MGMT protein that the tumor produces, the less effective the chemotherapy drug is expected to be.
-The production of the MGMT protein is controlled by the MGMT gene.
-Some tumor cells have a change in their MGMT gene called methylation that turns down the production of the MGMT protein.
- When MGMT is methylated, Temodar is effective in damaging glioma tumor cells.
-The MGMT test reports a percentage of methylation.

-Methyl Guanine Methyl Transferase (MGMT) Methylation status predicts the response of malignant glioma to chemotherapy and patients’ survival.
-MGMT is a protein in cells, including tumor cells, that repairs damage to the cell’s DNA caused by Temozolomide (Temodar) chemotherapy.
-The more MGMT protein that the tumor produces, the less effective the chemotherapy drug is expected to be.
-The production of the MGMT protein is controlled by the MGMT gene.
-Some tumor cells have a change in their MGMT gene called methylation that turns down the production of the MGMT protein.
- When MGMT is methylated, Temodar is effective in damaging glioma tumor cells.
-The MGMT test reports a percentage of methylation.